Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $408,095 | $388,151 | $183,586 | $157,147 |
| % Growth | 5.1% | 111.4% | 16.8% | – |
| Cost of Goods Sold | $160,821 | $169,624 | $156,748 | $253,769 |
| Gross Profit | $247,274 | $218,527 | $26,838 | $170,146 |
| % Margin | 60.6% | 56.3% | 14.6% | 108.3% |
| R&D Expenses | $19,472 | $21,555 | $15,729 | $25,280 |
| G&A Expenses | $114,546 | $55,527 | $58,053 | -$28,651 |
| SG&A Expenses | $251,395 | $186,224 | $183,998 | $181,890 |
| Sales & Mktg Exp. | $136,849 | $130,697 | $125,945 | $104,600 |
| Other Operating Expenses | $0 | $149,811 | $13,555 | $0 |
| Operating Expenses | $270,867 | $357,590 | $213,282 | $207,170 |
| Operating Income | -$23,593 | -$139,063 | -$186,444 | -$135,600 |
| % Margin | -5.8% | -35.8% | -101.6% | -86.3% |
| Other Income/Exp. Net | -$59,703 | -$51,024 | -$83,254 | -$9,987 |
| Pre-Tax Income | -$83,296 | -$190,087 | -$269,698 | -$145,587 |
| Tax Expense | $6,775 | -$21,468 | $47,745 | $74,501 |
| Net Income | -$93,836 | -$174,233 | $117,249 | -$209,481 |
| % Margin | -23% | -44.9% | 63.9% | -133.3% |
| EPS | -1.14 | -2.12 | -3.85 | -3.2 |
| % Growth | 46.2% | 44.9% | -20.3% | – |
| EPS Diluted | -1.14 | -2.12 | -3.67 | -3.2 |
| Weighted Avg Shares Out | 82,312 | 82,185 | 82,177 | 82,298 |
| Weighted Avg Shares Out Dil | 79,139 | 79,620 | 86,261 | 82,298 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $6,566 | $6,719 | $461 |
| Interest Expense | $34,888 | $34,501 | $10,454 | $32,098 |
| Depreciation & Amortization | $64,108 | $68,459 | $66,900 | $76,187 |
| EBITDA | $42,078 | -$87,127 | -$174,409 | -$46,340 |
| % Margin | 10.3% | -22.4% | -95% | -29.5% |